Clinical trial / 2005
Green tea extract demonstrated no objective responses in advanced lung cancer patients.
A phase I dose-escalation trial evaluated oral green tea extract in 17 patients with advanced lung cancer. The maximum tolerated dose was established at 3 g/m2 per day, with dose-limiting toxicities including nausea, diarrhea, and hypertension. No objective tumor responses occurred, though seven participants maintained stable disease for 4 to 16 weeks before progressing.
- Study type
- Phase I clinical trial
- Who was studied
- 17 patients with advanced lung cancer
- What was measured
- Maximum tolerated dose, toxicity, and objective tumor response
THE PAPER
Phase I study of green tea extract in patients with advanced lung cancer.
Laurie SA, Miller VA, Grant SC, Kris MG, Ng KK. Cancer Chemother Pharmacol, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.